Show simple item record

dc.contributor.authorMishra, M.V.
dc.contributor.authorKhairnar, R.
dc.contributor.authorBentzen, S.M.
dc.contributor.authorSun, K.
dc.date.accessioned2020-04-14T14:28:47Z
dc.date.available2020-04-14T14:28:47Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082776221&doi=10.1016%2fj.ctro.2020.03.003&partnerID=40&md5=cbba928a0e56a7f4f2d933c7312855de
dc.identifier.urihttp://hdl.handle.net/10713/12539
dc.description.abstractBackground: Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning (PS/US). This analysis compares patient reported outcomes (PRO) changes following PBS and PS/US for prostate cancer (PC) in a prospective multicenter registry study. Methods: We evaluated PROs with the Expanded Prostate Cancer Index Composite (EPIC) instrument for men with localized PC enrolled in PCG 001-09 (NCT01255748). PROs were assessed at baseline and through 12 months of follow-up. We compared mean changes in EPIC scores, as well as the proportions of men experiencing a one- and two-fold minimally important difference (MID) in domain scores, between PBS and PS/US. Multivariate analyses (MVAs) were performed to further evaluate the association between proton modality and PRO changes. Results: Three-hundred-and-four men completed EPIC at baseline; 72 received PBS and 232 received PS/US. The average quality-of-life (QOL) declines from baseline through 12 months did not significantly differ between the two groups. The proportion of men reporting a 1-MID decline at 12 months for PBS and PS/US was 34.3% and 27.4%, respectively, for urinary QOL (P = 0.27); 40. 1% and 40.9% for bowel QOL (P = 0.36); and 30. 1% and 36.6% for sexual QOL (P = 0.94). Corresponding 2-MID declines for PBS and PS/US were observed in 26.9% and 13.2% of men for urinary QOL (P = 0.01), 35.3% and 29.1% for bowel QOL (P = 0.33); and 16.4% and 18.1% for sexual QOL (P = 0.76). The association between proton modality and 2-MID changes in urinary QOL at 12-months remained significant on MVA (P = 0.007). Conclusions: The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12 months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted. Copyright 2020 The Authorsen_US
dc.description.sponsorshipAmerican Society for Radiation Oncology, ASTROen_US
dc.description.urihttps://doi.org/10.1016/j.ctro.2020.03.003en_US
dc.language.isoen_USen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofClinical and Translational Radiation Oncology
dc.subjectpencil beam scanningen_US
dc.subjectpassive scatter/uniform scanningen_US
dc.subject.lcshProstate--Canceren_US
dc.subject.meshProton Therapyen_US
dc.subject.meshPatient Reported Outcome Measuresen_US
dc.titlePatient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ctro.2020.03.003


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record